To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

643

Participants

Timeline

Start Date

October 20, 2017

Primary Completion Date

October 25, 2018

Study Completion Date

October 25, 2018

Conditions
Scalp Psoriasis
Interventions
DRUG

Calcipotriene/Betamethasone Dipropionate

Topical suspension 0.005%/0.064% (Glenmark Pharmaceuticals Ltd)

DRUG

Taclonex®

Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (LEO Pharma Inc.)

DRUG

Placebo

Placebo of Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (Glenmark Pharmaceuticals Ltd.)

Trial Locations (31)

11375

Investigational Site 29, Forest Hills

14623

Investigational Site 28, Rochester

23294

Investigational Site 23, Richmond

23507

Investigational Site 31, Norfolk

27262

Investigational Site 4, High Point

29464

Investigational Site 27, Mt. Pleasant

29644

Investigational Site 18, Fountain Inn

33027

Investigational Site 7, Miramar

33144

Investigational Site 1, Miami

33175

Investigational Site 30, Miami

33609

Investigational Site 22, Tampa

37215

Investigational Site 8, Nashville

37922

Investigational Site 9, Knoxville

40241

Investigational Site 21, Louisville

46617

Investigational Site 10, South Bend

47150

Investigational Site 15, New Albany

48103

Investigational Site 6, Ann Arbor

55432

Investigational Site 12, Fridley

64506

Investigational Site 26, Saint Joseph

77845

Investigational Site 11, College Station

78213

Investigational Site 16, San Antonio

78249

Investigational Site 19, San Antonio

78759

Investigational Site 5, Austin

80220

Investigational Site 14, Denver

89052

Investigational Site 17, Henderson

89128

Investigational Site 25, Las Vegas

90404

Investigational Site 32, Santa Monica

92024

Investigational Site 24, Encinitas

92108

Investigational Site 13, San Diego

92123

Investigational Site 20, San Diego

94538

Investigational Site 3, Fremont

All Listed Sponsors
lead

Glenmark Pharmaceuticals Ltd. India

INDUSTRY

NCT03331523 - To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis | Biotech Hunter | Biotech Hunter